viewImugene Ltd

Imugene outlines its focus on developing immuno-oncology treatments in half-yearly report

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

Imugene Ltd - Imugene increased net profits to more than $65 million for the year ending December 30, 2019
The company's PD1-Vaxx will be trialled in patients with lung cancer

Imugene Ltd's (ASX:IMU) focus of operations in the short to medium term will be directed towards the development of CF33 and PD1-Vaxx in a first in human studies as well as continued enrolment of the HER-Vaxx phase-2 study, as highlighted in its latest half-year report.

CF33 – a chimeric poxvirus

CF33 is a chimeric poxvirus derived through recombination among multiple strains of vaccinia virus and other species of poxvirus, making it better than a virus based on a single strain.

Preclinical data has demonstrated that CF33 is more efficacious than all parental viruses and some viruses in clinical trials.

CF33 efficiently shrank injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.

PD1-Vaxx study to begin in 2020

The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.

PD1-Vaxx will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.

The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

HER-Vaxx trial targeting HER-2 positive gastric cancer

The HER-Vaxx trial is targeting HER-2 positive gastric cancer, which was selected for this study as this type is not nearly as well served as breast cancer.

The Phase 1b stage of the study has been completed testing three different doses of the HER-Vaxx vaccine in combination with chemotherapy.

Phase 1b study met all key endpoints to identify the optimal dose of HER-Vaxx for the phase-2 study and Imugene continues to monitor the enrolment, data collection and the patient’s immune responses to the vaccine.

The company presented the Phase 1b study results of its HER-Vaxx B-cell immunotherapies at several international conferences around the world such as Chicago, Barcelona and Singapore during 2019.

Further patient data from Phase 1b will be published or presented at international conferences in 2020.

Quick facts: Imugene Ltd

Price: 0.032 AUD

Market: ASX
Market Cap: $141.63 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read